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Spirochetal diseases such as syphilis, Lyme disease, and leptospirosis are major threats
to public health. However, the immunopathogenesis of these diseases has not been fully
elucidated. Spirochetes interact with the host through various structural components such
as lipopolysaccharides (LPS), surface lipoproteins, and glycolipids. Although spirochetal
antigens such as LPS and glycolipids may contribute to the inflammatory response during
spirochetal infections, spirochetes such as Treponema pallidum and Borrelia burgdorferi
lack LPS. Lipoproteins are most abundant proteins that are expressed in all spirochetes
and often determine how spirochetes interact with their environment. Lipoproteins are
pro-inflammatory, may regulate responses from both innate and adaptive immunity and
enable the spirochetes to adhere to the host or the tick midgut or to evade the immune
system. However, most of the spirochetal lipoproteins have unknown function. Herein, the
immunomodulatory effects of spirochetal lipoproteins are reviewed and are grouped into
two main categories: effects related to immune evasion and effects related to immune acti-
vation. Understanding lipoprotein-induced immunomodulation will aid in elucidating innate
immunopathogenesis processes and subsequent adaptive mechanisms potentially rele-
vant to spirochetal disease vaccine development and to inflammatory events associated
with spirochetal diseases.
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INTRODUCTION
Spirochetes are the cause of important human diseases such as
syphilis, Lyme disease, and leptospirosis that are major threats
to public health (1). However, the immunopathogenesis of these
diseases has not been fully elucidated. Tissue inflammation is
characteristic of spirochetal diseases such as dermatitis in syphilis
and Lyme disease, interstitial nephritis in leptospirosis, and peri-
odontitis caused by oral treponemes (2, 3). Spirochetes such as:
Treponema pallidum (T. pallidum) and Borrelia burgdorferi (B.
burgdorferi), the pathogens for syphilis and Lyme disease, respec-
tively (1), may persist for prolonged periods despite the induced
immune responses in the host (4–6). Several mechanisms may
explain how spirochetes may evade host defenses such as intra-
cellular sequestration of the spirochetes, the antigenic variation
of the spirochetes, manipulation of host defenses to delay, and/or
suppress the onset of effective immune responses and structural
features of the outer membrane in spirochetes that contribute to
immune evasion (7–11).
Spirochetes have unique membrane structure that interacts
with the immune system (Figure 1) (2, 3, 12–18). Although spiro-
chetal antigens such as lipopolysaccharides (LPS), the main pro-
inflammatory component of Gram-negative bacteria (19), and
glycolipids may contribute to the inflammatory response dur-
ing spirochetal infections, spirochetes such as T. pallidum and
B. burgdorferi express abundantly membrane lipoproteins and
induce strong immune responses (20–24) despite lack of LPS (2,
3, 17, 18). Thus, lipid–lipid interactions between spirochetes and
the lipid rafts in eukaryotic host cells either through glycolipids
(3, 25, 26) or lipoproteins (2, 18, 22, 27–31) may occur and these
lipid interactions may be an important process that contributes to
the immunopathogenesis of spirochetal diseases (3, 25, 26).
In bacteria, membrane lipoproteins are important virulence
factors, pro-inflammatory agonists, enzymes, receptors, modu-
lar components of ATP binding cassette (ABC) transporters, and
protective immune targets that regulate innate immunity (2, 3).
In contrast to other bacteria that do not express lipoproteins so
abundantly (2, 3, 27), lipoproteins have an important role in the
virulence of spirochetes since they are most abundant proteins
that are expressed in all spirochetes (2, 3, 18, 22, 27–31). The spiro-
chetes express numerous lipoprotein genes [T. pallidum has >20
(24), B. burgdorferi has>100 lipoproteins (23), and approximately
8% of B. burgdorferi genes may encode lipoproteins (21, 23) and
Leptospira spp. Have >140 lipoprotein genes (32)]. Examples of
abundant lipoproteins in spirochetes include Tp47 of T. pallidum,
OspA of B. burgdorferi, LipL32 of Leptospira species, and Vmp
proteins of Borrelia species (Table 1). Finally, spirochetal lipopro-
teins have more prominent pro-inflammatory effects compared to
other bacterial lipoproteins and synthetic lipopeptides (28).
Surface-exposed lipoproteins often determine how spirochetes
interact with their environment and immunity (Figure 1) (2,
3, 18, 22, 27–31). Lipoproteins may be present in different cel-
lular compartments (2, 70, 84) and their distribution varies
among spirochetes (7, 18, 85–88) (Figure 1). The NH2-terminal
lipopeptide region is the part of the lipoprotein that confers
its immunologic activity since removal of this lipid component
removed the immunoregulatory properties of these lipoproteins
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FIGURE 1 | Structure of spirochetal membrane and lipoproteins. Similarly
to gram-positive bacteria, the spirochetal cytoplasmic membrane is
associated with the cell wall that consists of peptidoglycan. Similarly to
Gram-negative bacteria, spirochetes also have an outer membrane, which is
not attached to the peptidoglycan layer. Spirochetes differ phylogenetically
from Gram-negative bacteria and interact with the host through various
structural components such as lipopolysaccharides (LPS), surface lipoproteins
and glycolipids that are present mostly in the outer membrane. LPS has not
been identified in Borrelia andTreponema. The periplasmic space contains the
flagellum. The distribution of lipoproteins varies among spirochetes and they
may be present in different cellular compartments: the outer membrane, the
extracellular and the periplasmic spaces. For example the pro-inflammatory
lipoproteins ofT. pallidum are located below its cell surface and thus do not
interact directly with the immune system of the host. It has been suggested
that uptake and degradation ofT. pallidum releases lipoproteins and allows
their interaction with receptors on immune cells leading to immune cell
activation. Computational programs can predict spirochetal protein lipidation
but do not determine the location of lipoproteins in the cells. Recently,
developed fluorescence activated cell sorting (FACS) and surface proteolysis
methods can be used to screen for lipoprotein localization. Right upper
corner: structure of spirochetal lipoproteins. The finding of a cysteine residue
after a signal peptide (+1) is suggestive evidence that a protein is lipidated.
The spirochetal lipoproteins have a lipobox that is four amino acids in length
and mediates NH2-terminal lipidation on a conserved cysteine residue.
Lipoproteins interact with the phospholipids of membranes via three
hydrophobic N-terminal acyl moieties (often palmitate; C16) attached to a
N-terminal cysteine residue which may contribute to the localization of
spirochetal lipoproteins. An analysis of the fatty acids ofT. pallidum, B.
burgdorferi, L. interrogans phospholipids and lipoproteins found that while
fatty acids with different length side chains (C16 and C18) were found in
phospholipids, palmitate (C16) predominated in the lipoproteins. The
N-terminal tripalmitoyl-S-glyceryl-cysteine (Pam3Cys) lipid moiety is the part
of the lipoprotein that confers its immunologic activity. C, cysteine; LPS,
lipopolysaccharides.
while synthetic lipopeptides based on this lipid component could
activate immune cells (Figure 1) (7–11, 18, 28, 89–93).
In vitro and in vivo studies suggest that spirochetal membrane
lipoproteins and lipopeptides are pathogen-associated molecular
patterns (PAMPs) that bind to pattern recognition receptors such
as toll-like receptors (TLR1, 2). Thus, spirochetal lipoproteins are
pro-inflammatory (18, 33, 35–37, 41, 94) by activating endothe-
lial cells (36, 77–80, 95) and cells of innate immunity such as
macrophages and dendritic cells (DCs) (7–11, 38, 42–45, 56, 63, 96,
97). Spirochetal lipoproteins also enable the spirochetes to evade
the immune system (98, 99) and adhere to the host (100–104) or
the tick midgut (105, 106) (Table 1). Finally, lipoproteins may be
used as vaccine candidates for prevention of spirochetal infections
(2, 3). The immunoregulatory effects of spirochetal lipoproteins
have mostly been determined for major lipoproteins of T. pal-
lidum (e.g., Tp47), B. burgdorferi (e.g., OspA, B), and Leptospira
(e.g., LipL32) (Table 1). However, most spirochetal lipoproteins
have not been well-studied and their interplay with immunity has
recently been elucidated (Table S1 in Supplementary Material).
Different methods have been used (Table 2) but observations in
human models are often different from those obtained in vitro.
Lipoproteins are environmentally regulated and may be
expressed selectively during spirochetal infection (37, 50, 112–116)
(Table 1 in Supplementary Material). For example, the outer-
surface protein (Osp) A has a more important role in the patho-
genesis of borrelial infection during the tick phase of B. burgdorferi
and its expression is down regulated during the mammalian phase
of B. burgdorferi infection (9). Thus, although OspA does not have
a major role in regulation of host immunity in vivo, since it is not
expressed during the later stages of borrelial infection, it has been
used as a model to study in vitro the immunoregulatory effects
of spirochetal lipoproteins (9). Herein, the immunomodulatory
effects of spirochetal lipoproteins are reviewed and are grouped
into two main categories: effects related to immune evasion and
effects related to immune activation (Figure 2). Understanding
these mechanisms will aid in elucidating the immunopathogenesis
of chronic spirochetal diseases.
THE ROLE OF SPIROCHETAL LIPOPROTEINS IN IMMUNE
EVASION
Spirochetes may use outer membrane lipoproteins to invade
the host but host immunity may also target these lipoproteins.
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Table 1 | Immunoregulatory effects of major known spirochetal lipoproteins.
Spirochetal lipoproteins Endothelial cells Neutrophils Complement Antigen presenting cells: monocytes/
macrophages/DCs
Lymphocytes
Treponema pallidum: mixture
of bacterial lipoproteins of
various MW [17 kDA (33),
38 kDA (34), 47 kDA (35)] and
related synthetic lipopeptides
(22, 30)
Activate directly host
vascular endothelium
which plays important
roles in lymphocyte
homing and hemostasis
(36)
NR NR Stimulate macrophage and mDCs function:
costimulatory signals (DC-SIGN, CD14) (11,
37, 38) and production of chemokines (CCR5)
(39, 40), cytokines such as TNF-a, IL-1 beta,
IL-6, and IL-12 (18, 33, 35, 41) through TLRs
(42) and mostly TLR2 (43), activated IL-12 p40
promoter (42), NF-KB pathway (37, 38)
Up-regulate CCR5 expression on
CD4+T cells (39, 40)
Borrelia burgdorferi:
outer-surface protein A
(OspA) and B (OspB) and
related synthetic lipopeptides
(20, 44–46)
NR OspB inhibits the
phagocytosis and
oxidative burst of
human neutrophils
whereas OspA
induces the oxidative
burst in neutrophils
(47)
Deactivation of host
complement by
binding to CFH and
FHL-1 (47–49)
Stimulate macrophage function and
production of nitric oxide (42, 50),
chemokines (CXCL13) (51), pro-inflammatory
(such as TNF-a, IL-1 beta, IL-6, and IL-12) and
anti-inflammatory (IL-10) cytokines (18, 35,
41, 44, 52–55) through TLRs (28, 42, 44, 45,
56, 57), CD14, and NF-kB activation pathway
(37, 38, 44, 45). Also increase chemotaxis of
circulating pDCs into skin (11) but do not
activate pDCs in vitro and in vivo (58, 59)
Induce memory B cell immune
responses (60), B cell proliferation and
production of cytokines (61) and Th
production of cytokines (IFN-γ and IL-6)
(62) and chemokines (CXCL13) (51).
OspA may bind TLR 2 and 6, activate
NFκB and up-regulate costimulatory
molecules as well as of MHC class II,
leading to stronger T cell activation
(63–65); Possible molecular mimicry
for T helper cells between OspA-1 and
LFA-1 (66–68). OspA-1 may activate
autoreactive T cells against a
self-epitope and adaptive immune
responses to OspA are implicated in
the pathogenesis of antibiotic-
refractory Lyme arthritis (68, 69)
Leptospira interrogans LipL32
is the most abundant protein
on the outer membrane of
Leptospira and is expressed
at high levels during infection
(2, 70–76)
LipL32 interacts with
endothelial cells
contributing to systemic
inflammation (77–80)
NR NR The calcium-binding cluster is crucial for the
interaction between LipL32 and TLR2, which
then triggers the signaling cascade of
inflammatory responses (56, 72, 81)
Lipl32 has been used as immunogen
for vaccine trials (82, 83)
CFH, complement factor H; FHL-1, factor H-like protein 1; IL, interleukin; kDA, kilodalton; LipL32, 32-kDa lipoprotein of Leptospira; LFA-1, human lymphocyte function associated antigen 1; mDCs, myeloid dendritic
cells; MW, molecular weight; NF-kB, NF-kappa B; NR, not reported; OspA, outer-surface protein A; OspB, outer-surface protein B; pDCs, plasmacytoid dendritic cells; TLR, toll-like receptor;Th,T helper;TNF-a, tumor
necrosis factor.
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Table 2 | Methods used to determine in vitro and in vivo immunomodulatory properties of spirochetal lipopeptides/lipoproteins.
Method Comments
Mutagenesis systems • The lack of mutagenesis systems forT. pallidum significantly impairs studies of their
immunopathogenesis
• Mutagenesis systems for B. burgdorferi have recently been developed (107)
Structural studies • T. pallidum cannot be cultured in the laboratory and structural studies have been used to
elucidate the function of treponemal lipoproteins (108)
Synthetic lipopeptides • The immunomodulatory properties of lipopeptides are conferred by the lipid moiety of their
N termini and synthetic lipopeptides have been modeled after this structure to study native
spirochetal lipoproteins (18, 33, 35–37, 41, 94)
• The synthetic lipopeptides have qualitatively similar immunostimulatory properties to those
of native lipoproteins (18, 33, 35–37, 41, 94)
• Can be isolated in large amounts whereas large amounts of native lipoprotein cannot be
isolated from spirochetes that cannot be cultured such asT. pallidum
• LPS contamination is a major problem when purifying bacterial lipoprotein while synthetic
lipopeptides are synthesized under sterile conditions (22, 24, 35)
Skin techniques: injection of the skin with synthetic
lipopeptides
• Useful tools to study cellular responses induced by spirochetal lipopeptides within tissues
• Can be used instead of immunohistochemistry to characterize cellular infiltrates in target
tissues of spirochetal disease (40, 109, 110)
Identification of stereotypical responses to
lipopeptides in vitro (synthetic lipopeptides) and in vivo
(presence of similar histopathological abnormalities)
• Often contribute to the understanding of specific immunomodulatory effects of spirochetal
lipoproteins (6, 18, 37, 50, 61, 94, 111)
LPS, lipopolysaccharide.
However, all pathogenic spirochetes may cause persistent infec-
tions in humans by evading the host immune response through
multiple mechanisms such as limiting the expression of membrane
lipoproteins (85) and their access to antibodies (15, 117) and anti-
genic variation of surface lipoproteins (Table 1) (2, 98, 118–124).
Spirochetal lipoproteins may also interact with and inhibit com-
ponents of innate immunity such as the complement (10, 43, 56,
57, 97, 125–130), neutrophils, and serum lipoproteins (131).
SPIROCHETES USE ANTIGENIC VARIATION OF SURFACE LIPOPROTEINS
TO EVADE IMMUNITY
Antigenic variation in borrelias may result from recombination
of variable large and small protein genes (122) and the diver-
sity of Vmp lipoproteins allows these pathogens to evade the host
immune response (2, 3). Studies in immunocompromised hosts
have suggested that the host immune responses have a major role
in producing spirochetal antigenic variants (120).
SPIROCHETAL LIPOPROTEINS INHIBIT COMPLEMENT ACTIVATION
Spirochetes may evade immune responses by inhibiting comple-
ment, a major innate immune system of the host (132, 133).
Complement activation is caused by pathogen surface antigens
such as LPS, antigen–antibody complexes, and binding of lectin to
bacterial surfaces (134). Activation is regulated by host regulatory
proteins, including factor H (FH) (134). Borrelia bind comple-
ment regulator FH and/or FH-like protein 1 (FHL-1) by directly
interacting with Osp designated complement regulator-acquiring
surface proteins (CRASPs) (135). Numerous surface spirochetal
lipoproteins (outlined in Table 1; Table 1 in Supplementary Mate-
rial; Figure 2) such as OspA, OspE, CspA may contribute to
complement inhibition by binding to major complement regula-
tory proteins such as FH, FHL-1 C4b-binding protein (C4bp) and
human C1 esterase inhibitor (C1-Inh) (48, 99, 136–147). Thus,
spirochetal lipoproteins contribute to immune evasion through
complement inhibition.
SPIROCHETAL LIPOPROTEINS MAY INHIBIT NEUTROPHIL FUNCTION
Except for complement resistance, inhibition of neutrophil func-
tion is another mechanism that B. burgdorferi uses to evade
the immune system. OspB inhibits the phagocytosis and oxida-
tive burst of human neutrophils enabling B. burgdorferi to resist
phagocytosis and oxidative burst in areas such as joint, skin, and
the nervous system (47–49). Other spirochetal lipoproteins such
as LIC11207 in Leptospira spp. may up-regulate the apoptosis
of neutrophils (80). Thus, spirochetal lipoproteins may inhibit
neutrophil function which may help the survival of the spirochetes.
THE ROLE OF SPIROCHETAL LIPOPROTEINS IN IMMUNE
ACTIVATION
SPIROCHETAL LIPOPROTEINS MAY ACTIVATE NEUTROPHILS
Neutrophils are present in the joint fluid of Lyme arthritis patients
(1), suggesting that they contribute to immune responses against
B. burgdorferi. Although OspA and OspB are similarly regulated
in the life cycle of B. burgdorferi, they have different functions.
Contrary to OspB, OspA may activate human neutrophils (116)
induce their oxidative burst (47) and induce neutrophil chemo-
taxis (148). OspA and OspC up-regulate complement receptor
Frontiers in Immunology | Microbial Immunology June 2014 | Volume 5 | Article 310 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kelesidis Spirochetal lipoproteins and immunomodulation
FIGURE 2 | Summary of the role of known spirochetal lipoproteins in
regulation of immunity. Spirochetal lipoproteins have two different
major effects on immunity: immune evasion and immune activation.
These lipoproteins may contribute to immune evasion through inhibition
of complement, neutrophils, production of anti-inflammatory cytokines,
evasion of antibody responses through antigenic variation and binding to
other components of innate immunity (e.g., apolipoproteins). In addition,
spirochetal lipoproteins may directly promote spirochetal tissue invasion
and colonization and in combination with immune evasion may lead to
increased spirochetal replication and tissue inflammation. Spirochetal
lipoproteins may also directly and indirectly activate endothelial, epithelial
cells, and immune cells that contribute to innate immune responses
(neutrophils, monocytes, macrophages, and DCs) or adaptive immune
responses (lymphocytes such as B cells and CD4 T helper cells).
Collectively, these effects lead to increase inflammation in target tissues
(e.g., skin) or adaptive autoimmune responses (e.g., arthritis) that
contribute to the clinical manifestations of spirochetal diseases. IL,
interleukin; TNF-a, tumor necrosis factor A.
3 (CR3), an adhesion molecule expressed on neutrophils that is
involved in the interactions of Borrelia species with neutrophils
(149), and OspA and OspB may bind to CR3 in a C3bi indepen-
dent manner (150). Thus, different spirochetal lipoproteins may
inhibit neutrophils to evade immune responses but others may
activate neutrophils contributing to tissue inflammation.
SPIROCHETAL LIPOPROTEINS ACTIVATE MONOCYTES AND
MACROPHAGES TO SECRETE CYTOKINES THROUGH CD14 AND
TLR-DEPENDENT MECHANISMS
Bacterial lipoproteins and LPS both have an active lipid moiety
and induce similar cell responses in similar cell types (19). CD14
is a protein in the membrane of macrophages that binds LPS and
also induces lipoprotein signaling in several cells (38, 97, 151).
Cellular membrane CD14 activates myeloid cells such as mono-
cyte, macrophages, and polymorphonuclear white blood cells
while soluble CD14 activates non-myeloid (endothelial, epithelial)
cells (152). Spirochetal lipoproteins (such T. pallidum lipopro-
teins) bind to CD14 at the site that binds LPS and may acti-
vate monocytes and the NF-κB pathway through CD14 (38, 44,
97). In contrast to Gram-negative bacteria, LPS-binding protein
(LBP) does not mediate interaction of spirochetal lipoproteins
with CD14 (3, 38). However, TLR knockout and overexpres-
sion studies have confirmed that lipoproteins drive inflammation
in syphilis and Lyme disease through TLR-dependent (TLR1,
TLR2) responses (10, 43, 56, 57, 97, 125–130). Thus, during spiro-
chetemia in Lyme disease and syphilis, spirochetal lipoproteins
activate cells via TLR1 and TLR2 in contrast to Gram-negative
sepsis where cellular activation occurs through TLR4 (45, 56, 63).
Integrin α3β1 may co-operate with TLR2/TLR1 in mediating pro-
inflammatory responses in human macrophages stimulated with
spirochetal lipopeptides such as BBB07 (153, 154). However, TLR-
independent receptor responses are also important for spirochetal
induced inflammation (125, 154–156). T. pallidum lipoproteins,
the B. burgdorferi OspA lipoprotein and synthetic lipopetides
may up-regulate macrophage production of pro-inflammatory
cytokines such as TNF-α, IL-1, IL-6, and IL-12 (18, 50). Many
different cell types may produce IL-10 in response to stimula-
tion by B. burgdorferi lipoproteins (52, 53, 62, 157, 158). On
the other hand, endogenously produced and exogenous IL-10
www.frontiersin.org June 2014 | Volume 5 | Article 310 | 5
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significantly reduced OspA lipoprotein-induced macrophage pro-
duction of cytokines and chemokines (54, 62, 158–161), con-
sistently with previous studies that have shown that IL-10 may
down-regulate the TLR signaling pathway (159). Thus, spirochetal
lipoproteins induce immune responses in antigen presenting cells
such as monocytes and macrophages through TLR-dependent and
-independent mechanisms.
Spirochetal lipoproteins activate dendritic cells
Except for monocytes and macrophages, spirochetal lipoproteins
may also activate other antigen presenting cells such as DCs. DCs
are a major link between innate and adaptive immunity, since after
activation, they up-regulate costimulatory molecules such as CD54
that interact with T cell receptors such as CD11a/CD18 within
lymph nodes (162, 163). Consistent with the hypothesis that
lipoproteins are key pro-inflammatory mediators in spirochetal
diseases, many studies have shown that treponemal lipoproteins
and synthetic lipopeptides can up-regulate CD54 and contribute
to DC activation (18, 33, 35–37, 41, 94). Phagocytosis of intact
spirochetes, activation of TLRs at phagosomes and bacterial cell
death may result in the release of treponemal lipoproteins and may
also contribute to immune cell activation (163). Also B. burgdor-
feri lipoproteins increase chemotaxis of circulating plasmacytoid
dendritic cells (pDCs) into skin (11) but do not activate pDCs
in vitro and in vivo (58, 59).
SPIROCHETAL LIPOPROTEINS INDUCE INFLAMMATORY INFILTRATE
INTO TARGET TISSUES AND ADAPTIVE IMMUNE RESPONSES IN VIVO
THAT CONTRIBUTE TO CLINICAL MANIFESTATIONS OF SPIROCHETAL
DISEASES
Although lipoproteins may activate neutrophils, macrophages,
endothelial cells in vitro, they may also induce inflammatory
infiltrate into target tissues during spirochetal infection in vivo
(37, 50, 61, 94, 115, 116, 164). Lipoproteins may also contribute
to the pathogenesis of the Jarisch-Herxheimer reaction, a tran-
sient immunological phenomenon that occurs during treatment
of spirochetal infections (165, 166). Injection of synthetic lipopep-
tides into the skin can also be used to study the immunomodu-
latory effects of spirochetal lipoproteins in vivo (94). Cutaneous
injection of spirochetal lipopeptides and spirochetal skin infec-
tions elicit similar cellular infiltrate supporting the hypothesis that
spirochetal lipoproteins recruit diverse leukocytes from periph-
eral blood into target tissues (10). Lipoprotein-responsive cells
(167), such as endothelium (95, 168), keratinocytes (169), and
macrophages (170) induce chemotaxis of mixed cellular infiltrate
that in combination with extravasating leukocytes further increase
the tissue inflammatory response. Spirochetal lipoproteins acti-
vate in vivo antigen presenting cells (macrophages, DCs, CD4+ T
cells) within the inflamed skin in spirochetal diseases (39, 40, 58,
59). Lipopeptides in combination with other antigens from spiro-
chetes facilitate the transition from innate to prolonged adaptive
immune responses that contribute to chronic manifestations of
spirochetal diseases such as syphilis and Lyme disease (11). Con-
sistent with these data from in vivo studies, in vitro studies have
demonstrated that spirochetal lipoproteins may directly activate
both B and T cells (Table 1). These lipoprotein-induced adaptive
immune responses may trigger autoimmune and vaccine immune
responses (Table 1). Thus, spirochetal lipoproteins induce initially
innate immunity and then adaptive immunity through recruit-
ment of spirochete-specific T cells and tissue inflammation that is
associated with clinical manifestations of spirochetal disease such
as Lyme arthritis (37, 50, 94, 115, 116, 164).
CONCLUSION
Lipoproteins are widely expressed by many pathogens and have
pro-inflammatory effects (171–223). Thus, an understanding of
how lipoproteins interact with the immune system will aid in
the understanding of the pathogenesis of many infections includ-
ing spirochetal infections. In addition, elucidating the mole-
cular mechanisms of lipoprotein-induced immunomodulation
(summarized in Figure 2) will lead to a greater understand-
ing of the inflammatory processes, innate and adaptive immune
responses associated with spirochetal diseases that may contribute
to spirochetal disease vaccine development (163).
SUPPLEMENTAY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00310/
abstract
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